physiologically-based pharmacokinetic
Physiologically Based Pharmacokinetic Models for the Systemic Transport of Trichloroethylene
... These lipophilic environmental toxins, including TCE, can have both short-term and long-term adverse health effects on the population. It is important to assess the health risks these chemicals pose, so that the public ...
248
Toward a general physiologically-based pharmacokinetic model for intravenously injected nanoparticles
... Abstract: To assess the potential toxicity of nanoparticles (NPs), information concerning their uptake and disposition (biokinetics) is essential. Experience with industrial chemicals and pharmaceutical drugs reveals ...
16
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
... Background: Drug-drug interactions resulting from the inhibition of an enzymatic process can have serious implications for clinical drug therapy. Quantification of the drugs internal exposure increase upon administration ...
15
Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability
... silico physiologically based pharmacokinetic modeling ...FeSSIF. Pharmacokinetic clinical trial simulations were con- ducted using Simcyp (Version 14), incorporating P app and dissolution ...
16
<p>The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling</p>
... Objectives: Physiologically based pharmacokinetic (PBPK) modeling permits clinical scientists to reduce practical constraints for clinical trials on patients with special ...the ...
11
Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics
... Background: Cerium dioxide nanoparticles (nanoceria) are increasingly being used in a variety of products as catalysts, coatings, and polishing agents. Furthermore, their antioxidant properties make nanoceria potential ...
16
Utility of a single adjusting compartment: a novel methodology for whole body physiologically-based pharmacokinetic modelling
... human pharmacokinetic parameters from at least 2 animal species ...clinical pharmacokinetic parameters, uses in vitro materi- als such as hepatocytes and microsomes to scale up to an actual target ...
12
A Comparison of Physiologically-Based Pharmacokinetic (PBPK) Models of Methyl-Tertiary Butyl Ether (MTBE).
... for pharmacokinetic analysis estimation are noncom- partmental analysis (NCA), classical compartmental analysis, and physiologically-based pharmacokinetic ...
135
Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content
... a physiologically based pharmacokinetic model was utilized to interpret the effects of nanoparticle properties on previously published biodistribution ...A physiologically based ...
12
Compartmentalizing the Sunlight Vitamin: Physiologically Based Pharmacokinetic Modeling and Vitamin D.
... A pharmacokinetic model is a quantitative, rather than qualitative description of chemical behavior in biological systems over a period of ...tissues. Physiologically- based pharmacokinetic ...
140
Physiologically based pharmacokinetic (PBPK) modeling of benzene in humans: a Bayesian approach
... Physiologically based pharmacokinetic (PBPK) models are standard tools that are now often used in risk assessment to better extrapolate from experimental animals to humans and from high to low ...
33
A Parameter Analysis of a Physiologically Based Pharmacokinetic (PBPK) Model Describing the Movements of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the Mouse
... Although its mechanism of action is not completely understood, 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD) is an unfortunate environmental contaminant. In order to understand the effects of TCDD better, we examine a ...
69
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR PLANT BASED ANTI OXIDANT DRUGS
... Anti-oxidants are substances that are capable of counteracting the damaging but normal effects of the physiological process of oxidation in animal tissue. Anti-oxidants are nutrients (vitamins and minerals) as well as ...
7
A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles
... a physiologically based pharmacokinetic model (PBPK) was developed in this study for ionic silver and ...estimated based on the blood silver concentration of the respective experimental data ...
18
Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112
... The plasma concentration–time profiles displayed two distinct phases following intravenous administration of either the cosol- vent (control) or nanocrystals (Figure 5A). These two phases appear to be the distribution ...
15
Using publicly available data, a physiologically based pharmacokinetic model and Bayesian simulation to improve arsenic non cancer dose response
... RBALP: relative bioaccessibility leaching procedure; SBRC: Solubility/Bioavailability Research Consortium; UBM: BARGE Unified Bioaccessibility; RIVMa: National Institute for Public Healt[r] ...
25
Using publicly available data, a physiologically based pharmacokinetic model and Bayesian simulation to improve arsenic non cancer dose response
... BAc: bioaccessibility; RBA: relative bioavailability; IVIVC: in vitro and in vivo correlation; RBALP: relative bioaccessibility leaching procedure; SBRC: Solubility/Bioavailability Resea[r] ...
27
Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination
... overestimation of this parameter has already been noticed for another P-gp substrate, diazepam [23], and this bias translated into an overestimation of the brain concentration-time profile by at least a factor of three. ...
13
Applications of Physiologically Based Pharmacokinetic Models in Veterinary Medicine.
... Another source of variability within the population could be due to breed differences in metabolism and protein binding. To our knowledge, there are no reports of this in swine for sulfamethazine or for any other drug. ...
166
In vivo biodistribution and physiologically based pharmacokinetic modeling of inhaled fresh and aged cerium oxide nanoparticles in rats
... phagocytosis, but the model was limited to intravenous injection of nanoparticles. Kolanjiyil and Kleinstreuer [24] developed a multicompartment model for inhaled nanoparticles, but the model was based on ...
20